September 23, 2025
I am still of the opinion, “my hang-up or same-old mantra, every time I see a new high; I am of the opinion to say BYE.” And grab “some” with profit capacity
Prepping for the end of September as Q3 is coming to a close – 6 sessions to go
News: Moderna (MRNA +$0.24 or +0.90% pre-open) <see below>
Pre-Open Signals: 5 Positive and 2 Negative
Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!
September 22, 2025
Who is pumping the volume thus the price, after the usual small and inching volume or no volume is "suddenly" elevated 3506 shares trading (don't forget dive by half for buys and sells) - thus the pump.
Challenging and questionable "aspects" of today, Monday's (9/22) state the obvious – a Ponzi Scheme!
They’re BROKE filing with yet another PPM unfulfilled! What valuation model would even/ever justify a PPM pricing?
Accumulated deficit to date= $103.2 M
WHO is their major shareholder – DST Capital and itsDAILY buyer, OTCQB: HRGN’s in-house fund run by its president Hong Yu, funded by Mrs. bin (Zhao) of Weston, Mass. ???
U.S. investors BEWARE, forewarned is forearmed?
September 23, 2025
Overbought now oversold pronounces the alternating share pricing, so what’s sustainability again?
From the pre-open post, “I am still of the opinion, my hang-up or same-old mantra, every time I see a new high; I am of the opinion to say BYE.” And grab “some” with profit capacity”, As the cell and gene therapy sector romps through a volatile week’s
News: Solid Biosciences (SLDB +$0.16 OR +3.19% to $5.34) Licensing Agreement of Capsid AAV-SLB101 with Kinea Bio <see below>
Never leave an investor uninformed!
September 22, 2025
Who is pumping the volume thus the price, after the usual small and inching volume or no volume is "suddenly" elevated 3506 shares trading (don't forget dive by half for buys and sells) - thus the pump. Challenging and questionable "aspects" of today, Monday's (9/22) state the obvious – a Ponzi Scheme! They’re BROKE filing with yet another PPM unfulfilled! What valuation model would even/ever justify a PPM pricing? Accumulated deficit to date= $103.2 M WHO is their major shareholder – DST Capital and itsDAILY buyer, OTCQB: HRGN’s in-house fund run by its president Hong Yu, funded by Mrs. bin (Zhao) of Weston, Mass. ??? U.S. investors BEWARE, forewarned is forearmed?
September 15, 2025
Roche (RHO-DE: XETRA) confirmed it is staying put for now after fallout from drug pricing negotiations that saw the nation’s health minister walk away from talks. Merck (MRK) is moving all R&D operations out of UK, Eli Lilly (LLY) is pausing the build-out of UK biotech incubator,
August 28, 2025
Stay with me … Who is speaking-up for investors? I write this blog/newsletter about – facts in evidence! I will still answer or qualify the sector’s equity’s share pricing mobility; with an emphasis on which company is gaining or losing stride in your portfolio in the short and near-term I also follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
